CD44 and breast carcinoma: In support of this, a number of other studies have indicated that stem cell activity in breast cancer is not exclusively limited to the CD44+CD24−/low phenotype but that CD44+CD24+ can be equally tumourigenic in mouse xenograft models, most notably illustrated by Meyer et al. [40] in oestrogen receptor-negative disease.